All
Third-Quarter 2012 Financial Reports Show Novartis and Merck Down
October 30th 2012Pharmaceutical industry leaders Novartis and Merck—among others—released second-quarter 2012 results showing global sales down in third-quarter 2012, with growth in key pharmaceutical products helping to offset losses due to patent expirations.
GSK Encourages Open Innovation and R&D
October 15th 2012GlaxoSmithKline (GSK) has outlined the measures it is taking as part of a new open innovation approach to R&D, including opening up its tuberculosis compound library, investing in its open laboratory in Spain, and sharing detailed clinical trial data with researchers.
Grad Student Research Sparks Innovation through AAPS Awards
October 15th 2012At this week's AAPS 2012 Annual Meeting in Chicago, graduate students across the country are being honored for their research and work in bio/pharmaceutical innovation. BioPharm International had the chance to talk with a few of the recipients.
Novo Nordisk Expands R&D Facility in China
September 25th 2012Novo Nordisk is investing $100 million to expand its R&D facilities in Beijing, China. The company estimates that the new 12,000-m2 (129,167 ft2) center will make it possible to increase the number of science employees from the current 130 to 200, with extra space available to accommodate additional future growth.
CDER to Expand Office of Generic Drugs
September 11th 2012As a result of the passage of the Generic Drug User Fee Amendments Act, Janet Woodcock, director of the Center for Drug Evaluation and Research, announced her plan to reorganize the Office of Generic Drugs (OGD) into a super office that would include subordinate offices. The new super office would report directly to Director Woodcock, with Greg Geba continuing his role as OGD director.
Bristol-Myers Squibb Issues Voluntary Recall of Carmustine for Overfilled Vials
September 4th 2012Bristol-Myers Squibb has initiated a voluntary recall of 10 lots of BiCNU (carmustine for injection) previously manufactured by Ben Venue Laboratories, a former, third-party contract manufacturer for the company, to the user level.
EMA Seeks to Identify R&D Gaps in Pediatrics
September 3rd 2012The European Medicines Agency has launched a public consultation concerning its inventory of paediatric medicines with the aim of highlighting where further R&D efforts are required. The consultation is the first of its kind in this area.
Janssen Pharmaceuticals to Pay $181 Million in Multistate Consumer-Protection Suit
August 31st 2012The Johnson & Johnson subsidiary Janssen Pharmaceuticals has announced a settlement and consent decree with 36 states and the District of Columbia in regards to previously disclosed allegations related to the company's marketing and promotional practices relating to Risperdal (risperidone).